Literature DB >> 11394897

Morphological and physiological restorations of hereditary form of dilated cardiomyopathy by somatic gene therapy.

T Kawada1, A Sakamoto, M Nakazawa, M Urabe, F Masuda, C Hemmi, Y Wang, W S Shin, Y Nakatsuru, H Sato, K Ozawa, T Toyo-oka.   

Abstract

TO-2 strain hamsters with dilated cardiomyopathy, gene deletion of delta-sarcoglycan (SG) and no expression of alpha-, beta-, gamma-, and delta-SG proteins are useful for developing the potential gene therapy of intractable heart failure. We prepared recombinant adeno-associated virus vector including normal delta-SG gene driven by CMV promoter and intramurally administered in vivo. The transfected myocardium induced robust expression of both transcript and transgene for 2/3 period of the animal's life expectancy. Immunostaining demonstrated reexpression of not only delta-SG but also other three SGs in 40% cells in the transfected region and normalization of the diameter of transduced cardiomyocytes. Hemodynamic study revealed preferential amelioration of the diastolic indices (LVEDP, the dP/dt(min) and CVP). These results provide the first evidence that supplementation of a specific gene with efficient and sustained transfection capability restores the genetic, morphological, and functional deteriorations. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394897     DOI: 10.1006/bbrc.2001.4962

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.

Authors:  Tomie Kawada; Mikio Nakazawa; Sakura Nakauchi; Ken Yamazaki; Ryoichi Shimamoto; Masashi Urabe; Jumi Nakata; Chieko Hemmi; Fujiko Masui; Toshiaki Nakajima; Jun-Ichi Suzuki; John Monahan; Hiroshi Sato; Tomoh Masaki; Keiya Ozawa; Teruhiko Toyo-Oka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.

Authors:  Giuliana G Repetti; Christopher N Toepfer; Jonathan G Seidman; Christine E Seidman
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 3.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 4.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

5.  Sarcolemmal fragility secondary to the degradation of dystrophin in dilated cardiomyopathy, as estimated by electron microscopy.

Authors:  Tomie Kawada; Chieko Hemmi; Satoru Fukuda; Asaki Tezuka; Kuniaki Iwasawa; Mikio Nakazawa; Hiroshi Sato; Teruhiko Toyo-Oka
Journal:  Exp Clin Cardiol       Date:  2003

6.  Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction.

Authors:  Teruhiko Toyo-Oka; Tomie Kawada; Jumi Nakata; Han Xie; Masashi Urabe; Fujiko Masui; Takashi Ebisawa; Asaki Tezuka; Kuniaki Iwasawa; Toshiaki Nakajima; Yoshio Uehara; Hiroyuki Kumagai; Sawa Kostin; Jutta Schaper; Mikio Nakazawa; Keiya Ozawa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.